Please login to the form below

Not currently logged in
Email:
Password:

Osmotica Pharmaceuticals appoints new vice president

Samer Kaba joins the firm

Osmotica Pharmaceuticals has appointed Samer Kaba as vice president and head of global clinical development and medical affairs.

Kaba brings experience in developing pharmaceutical products for neurology, analgesia, and autoimmune diseases and has spent 15 years in the pharmaceutical industry in global clinical development programmes from early to late stage development and submission of NDAs and global marketing authorisations.

Praveen Tyle, president and CEO of Osmotica, said: “We are very pleased to have Samer as part of our senior leadership team at such an exciting time as he will be instrumental in further progressing Osmotica's recent achievements in our two lead CNS product candidates – Ontinua ER and Osmolex ER.

“Dr. Kaba's experience in multiple sclerosis will also be instrumental in discussions with FDA for the approval of Ontinua ER, which was accepted for filing by the FDA recently.”

8th October 2015

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics